Immco Diagnostics develops and distributes autoimmune disease diagnostics and reagents to labs worldwide. We offer laboratory testing of autoimmune diseases for the US healthcare market. Our contract research organization supports clinical research trials for pharmaceutical and biotech clients. Immco assay development led to the first immunofluorescence assay for diagnosing celiac disease and the first Western blot assay for autoimmune hearing loss. Our new line of enhanced ELISA assays provides standardized calibration systems, an industry first. We are continually expanding our product offering. So come visit us often as we focus on our principal mission at Immco—providing the total solution in autoimmunity™.
Immco offers a wide selection of autoimmune diagnostics under our leading brands: ImmuGlo™,ImmuLisa™, and ImmuBlot™
Immunofluorescence microscopy is the cornerstone of autoimmune diagnostics at Immco. As a leader in developing IFA (indirect immunofluoresence assays), we offer a full range of IFA products for detecting autoimmune disease. ImmuGlo™ is supported with flexible configurations and high quality reagents that ensure reproducibility and ease of use.
Immco ELISAs (enzyme linked immunosorbent assays) feature highly accurate qualitative and quantitative antibody detection for proper diagnosis of autoimmune disorders. Introduction of our new ImmuLisa™ Enhanced assays features industry leading advantages:
Immco's ImmuBlot™ uses Western blot assay methodology to provide highly sensitive, qualitative detection of autoantibodies in serum. ImmuBlot™ assays feature leading reliability and are primarily used to identify specific analytes or serve as confirmatory tests.
Immco Reference Lab Services, specializing in autoimmune diseases and immunopathology, provides laboratory testing with over 200 cutting edge diagnostics using direct and indirect immunofluorescence (IFA), enzyme linked immunosorbent assays (ELISA), Western blot detection methods and biopsy studies to support healthcare practitioners across a wide clinical spectrum. We provide histopathology and serology for oral diagnostics, autoimmunology and immunogenetics for common autoimmune diseases such as lupus, rheumatoid arthritis, celiac disease, polymyositis, systemic sclerosis, and thyroiditis, as well as the less prevalent autoimmune disorders. Our laboratory testing includes:
Immco is Proud to Announce FDA Approval of ImmuLisa Enhanced™ Celiac Fusion, a tTG/DGP ELISA detecting both human tissue transglutaminase (tTG) and deamidated gliadin peptide (DGP) antibodies of IgA and IgG isotypes and provides an ideal first line test for diagnosing celiac disease.
For more information on 5157 Celiac Fusion ELISA and all of Immco’s ELISA’s products, click on: http://www.immco.com/products/immulisa-elisa.aspx
Immco Diagnostics to participate at 9th International Congress on Autoimmunity in Nice, France March 26-30
Visit Immco Diagnostics at booth 8 during the Congress focused on Novel Diagnostic Tools & New Therapeutic Avenues in Autoimmune Diseases
© 2002-Present Immco Diagnostics, Inc. All rights reserved.
US/CAN: +1 800-537-8378 | Intl: +1 716-691-0091 | Fax: +1 716-691-0466 Revison Date 08-2011